irinotecan liposome (II) + temozolomide + fluzoparib
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ewing Sarcoma
Conditions
Ewing Sarcoma
Trial Timeline
Apr 15, 2025 → Feb 1, 2028
NCT ID
NCT06827717About irinotecan liposome (II) + temozolomide + fluzoparib
irinotecan liposome (II) + temozolomide + fluzoparib is a phase 2 stage product being developed by Sun Pharmaceutical for Ewing Sarcoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06827717. Target conditions include Ewing Sarcoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06827717 | Phase 2 | Recruiting |
Competing Products
14 competing products in Ewing Sarcoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Linsitinib | Astellas Pharma | Phase 2 | 52 |
| Abemaciclib + Irinotecan + Temozolomide | Eli Lilly | Phase 2 | 52 |
| IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) | Eli Lilly | Phase 2 | 52 |
| Xaluritamig | Amgen | Phase 1 | 32 |
| CP-751,871 | Pfizer | Phase 1 | 32 |
| CP-751,871 | Pfizer | Phase 1/2 | 40 |
| Palbociclib + Temozolomide + Irinotecan + Topotecan + Cyclophosphamide | Pfizer | Phase 2 | 51 |
| plerixafor + plerixafor + plerixafor | Sanofi | Phase 1/2 | 40 |
| regorafenib tablet | Bayer | Phase 1 | 30 |
| INCB059872 | Incyte | Phase 1 | 30 |
| Lurbinectedin | Jazz Pharmaceuticals | Phase 1/2 | 38 |
| Lurbinectedin | Jazz Pharmaceuticals | Phase 1/2 | 38 |
| Cabozantinib | Exelixis | Phase 1 | 30 |
| INBRX-109 + Irinotecan + Temozolomide + carboplatin + pemetrexed + Leucovorin + Fluorouracil | Inhibrx Biosciences | Phase 1 | 28 |
Other Products from Sun Pharmaceutical
Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85